Study to Assess PK, Safety and Tolerability in Healthy Subjects

NCT06380699 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

56

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Ischemic Stroke

Interventions

DRUG: QHRD106 Injection
DRUG: Human Urinary Kallidinogenase
DRUG: placebo

Sponsor

Changzhou Qianhong Bio-pharma Co., Ltd.